Left ventricular dysfunction after treatment with ipilimumab for metastatic melanoma

American Journal of Therapeutics

Volumn 23, Issue 6, 2016, Pages e1925-e1928

  Roth, Mary E ^a   Muluneh, Benyam ^a   Jensen, Brian C ^a,b   Madamanchi, Chaitanya ^a   Lee, Carrie B ^a,b,c  

^a UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Cardiotoxicity; Chemotherapy; CTLA 4 inhibitor; Drug related side effects and adverse reactions; Immunotherapy

Indexed keywords

CARVEDILOL; IPILIMUMAB; LISINOPRIL; METOPROLOL SUCCINATE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ABDOMINAL ABSCESS; ADULT; ANXIETY; ARTICLE; ATRIAL FIBRILLATION; CASE REPORT; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE CONTROL; DRUG TOLERABILITY; ECHOCARDIOGRAPHY; HEART EJECTION FRACTION; HEART LEFT BUNDLE BRANCH BLOCK; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART PALPITATION; HUMAN; HYPERTENSION; INCISIONAL HERNIA; LIVER INJURY; LIVER LOBECTOMY; LUNG EMBOLISM; MALE; METASTATIC MELANOMA; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAYNAUD PHENOMENON; THORAX PAIN; WIDE EXCISION; CHEMICALLY INDUCED; COMPLICATION; HEART BUNDLE BRANCH BLOCK; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; LIVER NEOPLASMS; MELANOMA; PATHOLOGY; SECONDARY; SKIN TUMOR;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ATRIAL FIBRILLATION; BUNDLE-BRANCH BLOCK; HUMANS; HYPERTENSION; LIVER NEOPLASMS; MALE; MELANOMA; MIDDLE AGED; SKIN NEOPLASMS; STROKE VOLUME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84958817747     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0000000000000430     Document Type: Article

References (10)

1. Blank CU, Enk A. Therapeutic use of anti-CTLA-4 antibodies. Int Immunol. 2014;27:3-10.
2. Yervoy (ipilimumab) [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2015:4.
3. Lichtman A. The heart of the matter: protection of the myocardium from T cells. J Autoimmun. 2013;45: 90-96.
4. Tivol EA, Borriello F, Schweitzer AN, et al. Loss of CTLA-4 leads to massive lymphoproliferative and fatal multiorgan tissue destruction, revealing a critical negative regulatory role for CTLA-4. Immunity. 1995;3: 541-547.
5. Geisler BP, Raad RA, Esaian D, et al. Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: a case of takotsubo-like syndrome. J Immunother Cancer. 2015;3:4.
6. Laubli H, Balmelli C, Bossard M, et al. Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J Immunother Cancer. 2015;3:11.
7. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-245.
8. Dickinson O, Chen LY, Francis GS. Atrial fibrillation and heart failure: intersecting populations, morbidities, and mortality. Heart Fail Rev. 2014;19:285-293.
9. Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014;27:911-939.
10. Higgins AY, O'Halloran TD, Chang JD. Chemotherapyinduced cardiomyopathy. Heart Fail Rev. 2015;20: 721-730.